Member Info for researcher1

thanks Phantom - I have had a look but not too keen on the expiry date aspect - could you explain how it works for you?

very important not to sell into small spikes like this morning - or even the large spike that will come with FDA approval - the major move will come once the dust has settled and the big boys feel the need to take Angle over.
Personally I'm onto CFDs now, to enable me to keep buying...

Cellsearch is most likely - not enough to trounce their IP, we also nick their best personnel...

the SP is still cheap IMO - but for Jupiter we'd be higher than this, at this point. Once FDA drops we will all wish we'd put the whole house in here (not just the half I used...)

I sense the conference on the 27th will drive the SP higher - it will be very much a "all ducks in a row" pitch to US investors, with compelling science and functionality. I said 70p by the end of the month, but that's beginning to seem conservative...

good level-headed plug in the MoS: htTps://www.dailymail.co.uk/money/investing/article-9154511/MIDAS-SHARE-TIPS-Gain-pounds-obesity-war.html tipped by the mail

yep, all looking good. Price to double before April?

traders selling out to get back in lower closer to the end of the trial - standard practice...
You may be right in your long term valuation, but 100M of it is possible by April.

SBTX won't need their cash though Phat, sales will generate multiples of that fund....

Rorke I think you need to read up on the Q process - saying the decision 'could go either way' is disingenuous. It is LIKELY to go the right way, so a heavy top slice (to obtain free ride) is not the correct strategy in this instance, on the balance of probability. There could be a delay (though we may not hear about it, just have to wait longer) but this is not a drug assessment, which could be rejected completely, it is a device submission, that has proven multiple efficacies and clear global health benefit - without any risk to patients.
p.s. a small top slice is never a bad thing.

Rorke I think you need to read up on the Q process - saying the decision 'could go either way' is disingenuous. It is LIKELY to go the right way, so a heavy top slice (to obtain free ride) is not the correct strategy in this instance, on the balance of probability. There could be a delay (though we may not hear about it, just have to wait longer) but this is not a drug assessment, which could be rejected completely, it is a device submission, that has proven multiple efficacies and clear global health benefit - without any risk to patients.

RD - "generally accepted" applies to this and another BB only - though Finncap did publish a note (OK, in-house broker) setting £1.50 target. The reason the SP is down here is due to Jupiter's stressed selling (they shorted Tesla). But for that, I'm convinced it would be nearly a quid now anyway ....

Darren you really should read up a little! - just go through the RNSs on this site for starters. FDA approval is anticipated 6 months after submission, which makes it end of March 2021, but IMO second half of April is more likely. Meanwhile there are two clinics about to open and an ovarian cancer study ongoing. SP was in the 70's before Covid delayed the submission but there has been dilution since then, so we are about back where we started, though now close to a company-changing event, which they are currently scaling up for, with sales team recruits, new IR personnel, new auditors (PWC), and new premises. So all is set for imminent lift off. I'd suggest however you think of these as a 2 year investment minimum, as the sheer scale of the opportunity is mind-blowing. Parsortix is peerless, top of the class, can find a needle in a haystack (well, the single live CTC in the blood sample) and will dominate a vast market for years to come.

are you attending the presentation on the 27th Rich? should be good detail, pitched at US investors, so SP likely 70p by end of month. Can you see it rising further than that prior to FDA? Expectation can do crazy things, and it now seems to be accepted that the SP will exceed £1 as and when it comes, probably flying past broker targets.

it seems like a triumph after Jupiter's shenanigans but it is only the base price

pleased to hear it Jel!

OPTI a cheap way into SBTX lift-off? - let's see....

totally right Phat

a modest RNS for a world-changing moment

thanks for the reminder elrico - ok then, IP "going cheap".....